[Federal Register: January 20, 2004 (Volume 69, Number 12)]
[Notices]               
[Page 2717-2718]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20ja04-40]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

 
Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.

    Name: Clinical Laboratory Improvement Advisory Committee 
(CLIAC).

[[Page 2718]]

    Times and Dates: 8:30 a.m.-5 p.m., February 11, 2004; 8:30 a.m.-
3:30 p.m., February 12, 2004.
    Place: Embassy Suites Hotel (Buckhead), 3285 Peachtree Rd. NE., 
Atlanta, Georgia 30305, Telephone: (404) 261-7733.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated; the 
impact on medical and laboratory practice of proposed revisions to 
the standards; and the modification of the standards to accommodate 
technological advances.
    Matters To Be Discussed: The agenda will include updates from 
CDC, the Centers for Medicare & Medicaid Services, and the Food and 
Drug Administration; a report from the CLIAC Waiver Workgroup; and 
discussion on the CLIA waiver criteria and process, previous CLIAC 
recommendations related to such, and AdvaMed's CLIA waiver criteria 
proposal.
    Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible.
    Oral Comments: In general, each individual or group requesting 
to make an oral presentation will be limited to a total time of five 
minutes (unless otherwise indicated). Speakers must also submit 
their comments in writing for inclusion in the meeting's Summary 
Report. To assure adequate time is scheduled for public comments, 
individuals or groups planning to make an oral presentation should, 
when possible, notify the contact person below at least one week 
prior to the meeting date.
    Written Comments: For individuals or groups unable to attend the 
meeting, CLIAC accepts written comments until the date of the 
meeting (unless otherwise stated). However, the comments should be 
received at least one week prior to the meeting date so that the 
comments may be made available to the Committee for their 
consideration and public distribution. Written comments, one hard 
copy with original signature, should be provided to the contact 
person below. Written comments will be included in the meeting's 
Summary Report.

FOR FURTHER INFORMATION CONTACT: Rhonda Whalen, Chief, Laboratory 
Practice Standards Branch, Division of Laboratory Systems, Public 
Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop 
F-11, Atlanta, Georgia 30341-3717; telephone (770) 488-8042; fax (770) 
488-8279; or via e-mail at RWhalen@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: January 13, 2004.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 04-1086 Filed 1-16-04; 8:45 am]

BILLING CODE 4163-18-P